Clinical Trials

166 enrolled 27 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

LymphoidOther hematologic neoplasmSarcoma

803 enrolled 4 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT05665530 2026-01-26

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

86 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT02296918 2025-12-19

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

69 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02242942 2025-11-06

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

445 enrolled 22 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04266795 2025-10-21

PEVENAZA

164 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT05105841 2025-10-15

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03069352 2025-09-30

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

211 enrolled 30 charts 3 FDA

Leukemia, Leukemia, Myeloid, Acute

NCT03112174 2025-07-22

SYMPATICO

366 enrolled 45 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT04477486 2025-07-09

Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma

13 enrolled 10 charts

Lymphoma, Mantle-Cell

NCT04214860 2025-03-17

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

51 enrolled 9 charts

Myeloid Malignancy

NCT02910583 2024-12-20

Captivate

323 enrolled 33 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04017546 2024-09-19

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

MyeloidOther hematologic neoplasm

14 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

120 enrolled 14 charts

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04887857 2024-02-12

OMNIVERSE

6 enrolled

Leukemia, Myeloid, Acute

NCT03672695 2024-02-05

Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.

37 enrolled

Leukemia, Myeloid, Acute

NCT03739554 2024-01-25

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

5 enrolled

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02005471 2023-10-17

MURANO

389 enrolled 35 charts 4 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04075747 2023-10-16

V-FAST

57 enrolled

Leukemia, Myeloid, Acute

NCT02611323 2023-10-10

A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

133 enrolled 39 charts

Lymphoma, Non-Hodgkin

NCT03873857 2023-09-01

FORTE

Completed

71 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02755597 2023-08-22

Bellini

291 enrolled 24 charts

Multiple Myeloma

NCT01682616 2023-06-06

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

49 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03236857 2023-05-22

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

CNSLymphoidOther hematologic neoplasm

143 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Neuroblastoma, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01794520 2023-04-10

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

117 enrolled 29 charts

Multiple Myeloma

NCT02756611 2023-04-10

VENICE I

258 enrolled 27 charts

Chromosome 17 deletion, Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03941964 2023-03-20

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

60 enrolled 12 charts

Neoplasms, Leukemia, Myeloid, Acute

NCT03312530 2023-02-28

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

49 enrolled 24 charts

Multiple Myeloma

NCT02980731 2023-02-22

VENICE II

210 enrolled 36 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03357627 2023-02-08

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

43 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT02141282 2022-12-19

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

127 enrolled 17 charts

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03873493 2022-12-19

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

14 enrolled 19 charts

Leukemia, Neoplasms, Recurrence, Leukemia, Prolymphocytic, T-Cell

NCT03082209 2022-12-09

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

GastrointestinalLymphoidOther hematologic neoplasm

153 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

NCT04038437 2022-11-09

A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML

35 enrolled

Leukemia, Myeloid, Acute

NCT02287233 2022-08-29

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

94 enrolled 37 charts

Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT04509622 2022-05-05

A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)

14 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT03000257 2022-04-14

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

BreastDermatologicGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

182 enrolled

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01328626 2022-02-23

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

222 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03441555 2022-02-01

A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

36 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT03255096 2022-01-24

A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6

39 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT02670044 2022-01-03

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

88 enrolled

Leukemia, Myeloid, Acute

NCT02639910 2021-12-20

COSMOS

24 enrolled 13 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01889186 2021-12-16

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

158 enrolled 21 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03181126 2021-10-14

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

69 enrolled

Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03625505 2021-09-14

A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

61 enrolled

Neoplasms, Recurrence, Leukemia, Myeloid, Acute

NCT01594229 2021-08-02

A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

60 enrolled

Lymphoma, Non-Hodgkin, Neoplasms

NCT01794507 2021-08-02

A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

66 enrolled

Multiple Myeloma

NCT02265731 2021-08-02

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

LymphoidOther hematologic neoplasmPlasma cell

38 enrolled

Lymphatic Diseases, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT01742988 2021-05-06

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

106 enrolled